Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide

4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide is listed in the pharmaceutical impurity collection under CAS 170571-00-3. Its represented structure has formula C17H14F3N3O3S and a calculated molecular weight of 397.38 g/mol.

2D chemical structure

H 2 N S O O N N F F F O H

Chemical identity

Catalog name
4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide
Common name
Not available
Chemical name
4-[5-[4-(hydroxymethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
CAS
170571-00-3
SMILES
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(CO)cc2)cc1
InChI
InChI=1S/C17H14F3N3O3S/c18-17(19,20)16-9-15(12-3-1-11(10-24)2-4-12)23(22-16)13-5-7-14(8-6-13)27(21,25)26/h1-9,24H,10H2,(H2,21,25,26)
InChIKey
ICRSYPPLGADZKA-UHFFFAOYSA-N
Associated API
Celecoxib

Record ID: A724418e7e573

Computed properties

C17H14F3N3O3S Molecular formula
397.378 g/molMolecular weight
397.0708 DaMonoisotopic exact mass
98.21 ŲTopological polar surface area
2.6978 Calculated LogP (Wildman–Crippen)
91.298 cm³/molMolar refractivity (Wildman–Crippen)
4 countHydrogen-bond acceptors
2 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 2 4 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C F H N O S 0 4 8 12 16 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight397.37868.89
Calculated LogP (Wildman–Crippen)2.697855.96
Topological polar surface area98.2170.98
Hydrogen-bond acceptors450.68
Hydrogen-bond donors264.87
Rotatable bonds (strict)449.39

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC17H14F3N3O3Sdimensionless
Molecular weight397.378g/mol
Monoisotopic exact mass397.0708Da
Topological polar surface area98.21Ų
Calculated LogP (Wildman–Crippen)2.6978dimensionless
Molar refractivity (Wildman–Crippen)91.298cm³/mol
Hydrogen-bond acceptors4count
Hydrogen-bond donors2count
Rotatable bonds (strict)4count
Heavy atoms27count
Heteroatoms10count
Rings3count
Aromatic rings3count
Aliphatic rings0count
Saturated rings0count
Aromatic heterocycles1count
Aliphatic heterocycles0count
Saturated heterocycles0count
Aromatic carbocycles2count
Aliphatic carbocycles0count
Fraction of sp³ carbon atoms0.1176fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters0count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area152.2742Ų
Valence electrons142count
Radical electrons0count
Bertz complexity1,057.5434index
Balaban J2.1397index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide

Qualification and safety assessment of 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide

Explore toxicological qualification of 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide and ICH M7 mutagenic impurity assessment of 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide and acceptable intake and limit justification for 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for 4-[5-[4-(Hydroxymethyl)phenyl]-3- (trifluoromethyl)-1H-pyrazol-1-yl]- benzenesulfonamide

Explore Altox services and software through the Altox Pharma-Hub.